



**FY 21 President’s Request for BA Appropriations for FDA, Compared with FY 19 and FY 20 Funding**

ANALYSIS as of February 10, 2020 at 2 p.m.—Subject to change.

Source: [https://www.whitehouse.gov/wp-content/uploads/2020/02/hhs\\_fy21.pdf](https://www.whitehouse.gov/wp-content/uploads/2020/02/hhs_fy21.pdf)

**Some columns may not add due to rounding**

| Budget Line—BA only<br>“Salary and Expenses” | FY 19                   | FY 20 Final            | FY 21 President’s<br>Request 2/10/20 |
|--|-------------------------|------------------------|--------------------------------------|
| Food   | \$ 1.060 billion        | \$1.089 billion        | \$1.091 billion                      |
| Human Drugs                                  | \$ 663 million          | \$ 683 million         | \$ 683 million                       |
| Biologics                                    | \$ 240 million          | \$ 252 million         | \$ 252 million                       |
| Animal Drugs and Feeds                       | \$ 179 million          | \$ 191 million         | \$ 190 million                       |
| Devices/Rad Health                           | \$ 387 million          | \$ 395 million         | \$ 416 million                       |
| National Center Tox. Research                | \$ 67 million           | \$ 67 million          | \$ 66 million                        |
| Office of the Commissioner                   | \$ 188 million          | \$ 185 million         | \$ 187 million                       |
| All rent items; WO consolidation             | \$ 285 million          | \$ 297 million         | \$ 321 million                       |
| <b>Budget Authority Total</b>                | <b>\$ 3.069 billion</b> | <b>\$3.160 billion</b> | <b>\$3.206 billion</b>               |

Without adjustments for rounding, our preliminary analysis is that the President’s proposal is for a \$46 million increase in the BA (taxpayer funded) appropriations. This breaks out as: \$2 million additional for food; \$21 million additional for devices; \$2 million additional for programs in the Commissioner’s office; and \$24 million in total rent items. Offsetting this are: \$1 million decreases for animal drugs and the National Center for Toxicological Research. Some of the year-to-year variance may be rounding and not substantive.

We are likely to have further adjustments when we see the full Congressional Justification (300+ pages) that supports the request for FDA.

-----

21<sup>st</sup> Century Cures/FDA Innovation Fund monies come from reductions in mandated spending; not included in BA appropriations totals. In FY 20, this added \$75 million to resources available to FDA for specified purposes. The comparable number in FY 21 is \$70 million, which is consistent with the statute.

For more information, contact Steven Grossman, the Deputy Executive Director of the Alliance for a Stronger FDA:  
[sgrossman@strengthenfda.org](mailto:sgrossman@strengthenfda.org) or 301-539-9660